UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2025

Commission File Number: 001-41842

Abivax SA

(Translation of registrant’s name into English)

7-11 boulevard Haussmann

75009 Paris, France

+33 (0) 1 53 83 08 41

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On April 22, 2025, Abivax SA (the “Registrant”) published a press release entitled “Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones.” A copy of the notice is furnished as Exhibit 99.1 to this Report on Form 6-K and is incorporated herein by reference.

Also on April 22, 2025, the Registrant announced the appointment of Dominik Höchli, MD to the Registrant’s Board of Directors, effective as of April 22, 2025. A copy of the press release announcing the appointment is furnished as Exhibit 99.2 to this Report on Form 6-K and is incorporated herein by reference.

Incorporation by Reference

Exhibit 99.2 hereto, except for the quotes contained therein, shall be deemed to be incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-283336) and Form S-8 (File No. 333-286069) and to be part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed.

Exhibit Index


Exhibit 99.1		Press Release, dated April 22, 2025

Exhibit 99.2		Press Release, dated April 22, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


						Abivax SA
						(Registrant)

Date: April 22, 2025						/s/ Marc de Garidel
						Marc de Garidel
						Chief Executive Officer

Abivax S.A. 6-K